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Abstract
Introduction : Maturity onset diabetes of the young due to HNF1A mutations (HNF1A-MODY) is the most frequent form of monogenic diabetes in 
adults. It is often misdiagnosed as type 1 or type 2 diabetes, but establishing genetic diagnosis is important, as treatment differs from the common 
types of diabetes. HNF1A-MODY has not been investigated in Croatia before due to limited access to genetic testing. In this study we aimed to des-
cribe the characteristics of young adults diagnosed with diabetes before the age of 45 years, who have rare HNF1A allele variants, and estimate the 
prevalence of HNF1A-MODY in Croatia.
Materials and methods : We recruited 477 C-peptide positive and beta cell antibody negative subjects through the Croatian Diabetes Registry. 
HNF1A was sequenced for all participants and systematic assessment of the variants found was performed. The prevalence of HNF1A-MODY was 
calculated in the study group and results extrapolated to estimate the proportion of diabetic individuals with HNF1A-MODY in Croatia and the popu-
lation prevalence. 
Results : Our study identified 13 individuals harbouring rare HNF1A allelic variants. After systematic assessment, 8 were assigned a diagnosis of 
HNF1A-MODY. Two individuals were able to discontinue insulin treatment following the diagnosis. We estimated that HNF1A-MODY in Croatia has a 
prevalence of 66 (95% CI 61 - 72) cases per million.
Conclusions : The estimated prevalence of HNF1A-MODY in Croatia is similar to that reported in other European countries. Finding cases lead to 
important treatment changes for patients. This strongly supports the introduction of diagnostic genetic testing for monogenic diabetes in Croatia.
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Introduction
Maturity-onset diabetes of the young (MODY) is a 
clinically heterogeneous group of disorders, 
caused by mutations in one of 13 different genes 
(1). One of the most frequent forms of MODY is as-
sociated with variants in the HNF1A (hepatocyte 
nuclear factor 1-alpha) gene on chromosome 12, 
also known as HNF1A-MODY. HNF1A is expressed 
in beta cells, where it encodes a crucial member of 
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the auto-regulatory transcriptional network dur-
ing embryonic development of pancreas (2). In 
adult life, protein HNF1A regulates the expression 
of numerous beta cell genes, such as insulin, pyru-
vate kinase and the glucose transporter molecule 
Glut2 (3).
Subjects harbouring disease-causing HNF1A allelic 
variants typically present with prominent family 
history of diabetes (autosomal dominant mode of 
inheritance), early onset of diabetes (classically be-
fore the age of 25 years) and insulin independence 
evidenced by presence of C-peptide, often despite 
a long duration of diabetes (4). The majority of 
subjects with MODY do not show signs of insulin 
resistance and their body mass index (BMI) is in 
the normal range. The disease is characterized by 
progressive deterioration of beta cell function, 
due to an inability to increase insulin secretion in 
response to hyperglycaemia (5). Disease-causing 
variant alleles in HNF1A demonstrate a high pene-
trance, so 63% of variant carriers develop diabetes 
before 25 years of age, and 96% before the age of 
55 years (6). 
MODY is frequently misdiagnosed as type 1 or 
type 2 diabetes due to low awareness among pri-
mary care physicians, lack of widely accepted di-
agnostic protocols and/or unavailability of genetic 
testing. Definitive diagnosis of HNF1A-MODY is es-
tablished by sequencing of HNF1A, although con-
firmation that allelic variants are disease-causing 
remains a challenge. A correct molecular diagnosis 
is of utmost importance, since subjects with HN-
F1A-MODY are usually very sensitive to oral treat-
ment with sulphonylurea derivatives (SU) such as 
gliclazide, which can provide excellent diabetes 
control for decades (7). Glinides have similar mech-
anism of action to SU, therefore are an alternative 
treatment for HNF1A-MODY (8). Establishing a ge-
netic diagnosis of HNF1A-MODY may lead to treat-
ment changes for previously misdiagnosed pa-
tients, even to the discontinuation of assumed life-
long insulin treatment. Correctly identifying MODY 
subjects also allows the recognition of affected 
family members, thereby enabling better disease 
management and clinical care for these individu-
als too.  
The current diagnostic pathways for MODY, which 
mostly include clinical criteria, miss many cases 
through low sensitivity (9,10). Maturity-onset dia-
betes of the young is rarely diagnosed in Croatia 
because genetic testing is not available to most 
clinicians. Therefore, the prevalence of MODY in 
Croatia has never been studied. The goal of the 
study was to describe the clinical characteristics of 
Croatian subjects with HNF1A-MODY, estimate the 
prevalence of HNF1A-MODY within Croatian sub-
jects diagnosed with diabetes as young adults, in-
crease the awareness of this specific type of diabe-
tes and thus provide support for introduction of 
genetic testing for monogenic diabetes in Croatia.
Materials and methods
Subjects
Initial recruitment was performed using data from 
the Croatian national registry of patients with dia-
betes (CroDiab); a registry established to improve 
health care, to determine the prevalence and inci-
dence of diabetes and its complications, as well as 
to monitor morbidity and mortality at the national 
level (11). All primary and secondary care physi-
cians who provide diabetes care were obliged to 
supply data on their patients to the Vuk Vrhovac 
University Clinic for Diabetes, Endocrinology and 
Metabolic Diseases on an annual basis until 2015 
(12). Data supplied constitutes a basic informatic 
sheet, recognised by the international diabetology 
community as optimal data collection form for the 
follow-up and improvement of diabetes care. 
All adult subjects with diabetes onset under age of 
45 years and currently older than 18 years were eli-
gible to take part in the study. Other inclusion cri-
teria encompassed the following: evidence of en-
dogenous insulin secretion (fasting or random C-
peptide ≥ 0.2 nmol/L) and negative glutamic acid 
decarboxylase antibodies (GADA) and islet cell au-
toantibodies (ICA). Letters of invitation, describing 
the protocol and aims of the study, were sent to 
the home address of eligible subjects. Subjects 
newly diagnosed with diabetes who met inclusion 
criteria were also invited to participate. Study par-
ticipants were recruited at Vuk Vrhovac University 
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Clinic for Diabetes, Endocrinology and Metabolic 
Diseases, Merkur University Hospital, Zagreb; 
the Reference Centre for Diabetes of the Croatian 
Ministry of Health, in the period between June 
2013 and June 2015. Whole blood and plasma 
samples were collected from every patient. Blood 
was collected into EDTA-treated tubes and plasma 
was separated by centrifugation. All samples were 
stored at -20 °C until further analysis.
Data collection included the following informa-
tion: age, sex, age of diabetes onset, treatment his-
tory, current medication, family history of diabe-
tes, anthropometrical data (weight, height, body 
mass index (BMI), blood pressure) and biochemical 
data (fasting glucose, glycated haemoglobin 
(HbA1c), C-peptide, lipid profile, creatinine). All re-
cruited participants gave written informed con-
sent. The study was approved by Ethics Commit-
tee of Merkur University Hospital and Faculty of 
Pharmacy and Biochemistry, University of Zagreb, 
Croatia. The study was conducted in accordance 
with the Declaration of Helsinki.
Study design
Figure 1 illustrates the study recruitment strategy. 
Study participants were mainly recruited through 
CroDiab registry. According to the study inclusion 
criteria there were 13,035 adult subjects with dia-
Figure 1. Flowchart showing the study recruitment strategy
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betes onset before the age of 45 years. Patients in 
CroDiab were prioritized for invitation if GADA was 
analysed at the Reference Centre for Diabetes, 
which participated in an antibody standardization 
programme. From the list of eligible individuals, 
2929 subjects who fulfilled the inclusion criteria 
were invited to participate from throughout Croa-
tia. For subjects without existing beta cell anti-
body analysis, the antibodies were assayed prior 
to the inclusion into the study. Three hundred and 
twenty-five subjects were recruited; others did not 
respond or declined to participate. A further 148 
recently diagnosed subjects were recruited during 
their visit to the Vuk Vrhovac University Clinic. Lat-
er on, additional 14 family members were recruit-
ed for co-segregation studies. Of these, 10 did not 
have diabetes, resulting in a total of 477 individu-
als with diabetes recruited in the study. 
Methods 
Biochemical and immunological assays
Plasma glucose and serum lipid profile were as-
sayed using routine enzymatic methods (AU680, 
Beckman Coulter, Brea, USA) in the accredited 
(ISO15 189:2012) laboratory. HbA1c was measured by 
turbidimetric immuno-inhibition traceable to the 
IFCC-reference system and reported in DCCT-
aligned units (AU680, Beckman Coulter, Brea, USA), 
with a total imprecision (CV) of 1.8%. C-peptide was 
analysed using a chemiluminescence immunoassay 
on the Advia Centaur XP analyser (Siemens Health-
care Diagnostics, Eschborn, Germany) with a CV of 
5.6%. Islet cell antibodies were measured by indi-
rect immunofluorescence. Rate of positivity was cal-
culated by determining end-point titres of samples 
that were converted to the units of Juvenile Diabe-
tes Foundation (JDF-U) by comparison with a stand-
ard curve of log 2 JDF units with log 2 of end-point 
titre of standard sera. The threshold of detection 
was > 5 JDF units. Glutamic acid decarboxylase an-
tibodies were measured by enzyme-linked immu-
nosorbent assay (ELISA) (Euroimmun AG, Lübeck, 
Germany). The cut-off for the positive result was set 
to 5 WHO Units/mL. Analysis were performed in a 
laboratory participating in the international harmo-
nisation programme (DASP; Diabetes Antibody 
Standardization Program) (13).
HNF1A sequencing and analysis of the HNF1A 
variants
Deoxyribonucleic acid (DNA) was extracted from 
the whole blood sample using QIAmp DNA Mini 
Blood kit (Qiagen, Hilden, Germany), according to 
the manufacturer’s protocol (14).
Quantity and quality of the extracted DNA were 
evaluated using Nanodrop 8000 UV-Vis spectro-
photometer (Thermo Scientific, Waltham, USA). 
Both were satisfactory, with an average DNA con-
centration of 38.69 (6.49 – 107.60) ng/µL and aver-
age A260/A280 ratio of 1.84 (1.46 – 2.66).
Extracted genomic DNA (2.5 µg) was amplified by 
polymerase chain reaction and sequenced bidi-
rectionally by Sanger sequencing, using forward 
and reverse primers for all 10 HNF1A exons. Prim-
ers were ordered from Eurofins MWG Operon 
(Ebersberg, Germany) according to a published se-
quence (15). Sequencing was performed at the Di-
abetes Research Laboratory of the Oxford Centre 
for Diabetes, Endocrinology and Metabolism, UK. 
The final sequencing read was obtained using ABI 
3730 capillary sequencer (Aplied Biosystems, 
Birchwood, UK). The frequency of known common 
variants such as p.L17L, p.I27L, and p.A98V was 
compared to their minor allele frequency (MAF) in 
the 1000 Genomes database (0.44 vs. 0.41, 0.29 vs. 
0.30, 0.05 vs. 0.02, respectively). Variants p.I27L and 
p.A98V were also genotyped and had a mean of 
1.1% and 0.3% discordance rate, when compared 
to the Sanger sequencing result.
Analysis of sequencing was performed in Muta-
tion Surveyor version 5.1 (Soft Genetics, Cam-
bridge, UK). Disease causality of variants was as-
sessed taking into account clinical features, co-
segregation of diabetes in affected family mem-
bers (where available) and in silico analysis of mis-
sense variants using SIFT (Sorting Intolerant From 
Tolerant), Polyphen2 (PPH2) and Provean bioinfor-
matics tools (Figure 2). Identified variants were 
also assessed for their presence in publically avail-
able databases (Exome Sequencing Aggregation 
Consortium, ExAC, Broad Institute, Boston, USA) 
and in the 12,940 exomes from the T2D-GENES 
study comprising participants with type 2 diabe-
tes mellitus (T2D) and non-diabetic controls which 
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are also included in ExAC populations (http://www.
type2diabetesgenetics.org). Although details of di-
abetic status are not available for ExAC participants 
and it would not be impossible for a patient with 
MODY to be included, in general, presence of the 
variant in a population cohort would suggest that 
the variant is not disease-causing.
Statistical analysis
Non-parametric summary measures were used to 
describe the groups (subjects with a rare HNF1A al-
lelic variant (N = 13) and without the HNF1A vari-
ants (N = 464)). Medians with ranges (min - max) 
were calculated for non-parametric continuous 
variables (current age, age at diagnosis, duration 
of diabetes, BMI, HbA1c and C-peptide, lipid profile) 
and percentages for categorical measures (gender 
and current treatment). Non-parametric statistics 
(Mann-Whitney test) were used for comparison of 
continuous variables among groups. Differences 
of frequencies for categorical variables were test-
ed using the Chi-squared (treatment) and Fisher’s 
test (gender). Significant differences were as-
sumed for P < 0.05. The prevalence of HNF1A-MO-
DY among subjects with diabetes was calculated 
as the proportion of individuals with HNF1A-MO-
DY out of the total number of participants and ex-
trapolated to calculate estimated population prev-
alence using the latest available data (year 2015) 
from the Croatian Institute of Public Health. Statis-




Basic anthropometric and clinical data of the re-
cruited subjects are given in Table 1. None of the 
participants were known to have monogenic dia-
betes before the study. Subjects with diabetes and 
a rare HNF1A allelic variant were predominantly fe-
males (P = 0.02). Their median (min - max) age (in-
cluding both probands and affected relatives) was 
48 (18 - 72) years, their median age at diagnosis of 
diabetes was 35 (16 - 50) years and their median 
diabetes duration was 10 (2 - 31) years. We found 
no significant differences between diabetic sub-
jects with or without a rare HNF1A allelic variant re-
garding their current age, age at onset and dura-
tion of diabetes. The subjects with a rare HNF1A 
variant had lower median BMI compared to sub-
jects without a rare HNF1A variant (P = 0.003). Lipid 
profile also showed differences between the 
groups. Median HDL-cholesterol was higher (1.4 vs. 
1.2 mmol/L, P = 0.024) and median triglycerides 
were lower (1.1 vs. 1.6 mmol/L, P = 0.015) in those 
with HNF1A variants compared to those without. 
Figure 2. Systematic assessment of identified HNF1A variants. MAF - minor allele frequency. MODY - Maturity-onset diabetes of the 
young. SIFT - Sorting intolerant from tolerant. 
Sanger sequencing of recruited
participants
9 HNF1A variants with MAF < 1%
SIFT Polyphen 2 Provean
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  Diabetes and no rare 
HNF1A variant
Diabetes and rare HNF1A 
variant
P-value†
N 464 13*  
Gender (males, % or proportion) 58 3/13 0.020
Age (years) 47 (18 - 78) 48 (18 - 72) 0.571
Age at diagnosis (years) 37 (5 - 47) 35 (16 - 50) 0.142
Duration of diabetes (years) 11 (0 - 45) 10 (2 - 31) 0.444
BMI (kg/m2) 29.6 (15.5 - 53.2) 24.1 (19.1 - 38.4) 0.003
Current treatment: 0.005
 - Oral glucose-lowering agents (% or proportion) 52 2/13 NP
 - Insulin therapy (% or proportion) 13 3/13 NP
 - Insulin + oral agents (%) 23 2/13 NP
 - Diet only (% or proportion) 11 5/13 NP
 - Unavailable/without therapy (%) 2 1/13 NP
HbA1c (%) 7.3 (3.9 - 14.2) 6.8 (5.3 - 11.9) 0.094
C-peptide (nmol/L) 0.73 (0.21 - 3.81) 0.33 (0.22 - 1.56) 0.006
Continuous variables are given as median and interquartile range, age is given as median (min - max), while categorical variables are 
given as percentages. *The number excludes one recruited relative with a rare HNF1A allelic variant, but without diabetes.†P-values 
were calculated using Mann-Whitney U test (significance level α = 0.05); for categorical variables Chi-square (treatment) and Fisher’s 
(gender) tests were used. NP - statistical analysis was not performed due to too small sample size. BMI - body mass index. HbA1c - 
glycated haemoglobin.
Table 1. Characteristics of the study participants
Current medical treatment differed significantly 
between the subjects with a rare HNF1A variant 
and subjects without a rare HNF1A variant (P = 
0.005). The majority of the subjects with a rare HN-
F1A allele variants received dietary intervention 
only (39% compared to 11% in the group without 
an HNF1A variant), while the majority of subjects 
without the variants were treated with oral glu-
cose-lowering agents only (51.7% compared to 
15.4% in HNF1A group). Among the subjects with a 
rare HNF1A variant, one was treated with a sulpho-
nylurea derivative and two with a glinide.
We observed no significant difference in HbA1c val-
ues between the groups, but subjects with diabe-
tes and an HNF1A variant had lower C-peptide val-
ues (P = 0.006). 
Among subjects with an HNF1A variant, 12 had at 
least a two-generational family history of diabetes, 
whilst detailed family histories were unavailable for 
one proband due to loss of contact with relatives. 
HNF1A variants identified in the study 
Sequencing of HNF1A gene identified 9 rare non-
synonymous HNF1A allelic variants, including 3 
protein truncating (PTV) and six missense variants 
(Table 2), in 9 probands and 5 relatives (1 without 
diabetes). 
The PTVs and the protein variant p.P379R were 
previously reported in subjects with HNF1A-MO-
DY, while the protein variant p.A251T was identi-
fied previously in a patient with SU-sensitive dia-
betes (16,17). Protein variants p.G288W and p.
T515M have not been previously reported in 
MODY families. However, variants with a different 
amino acid change at the same position (namely, 
p.G288C and p.T515K) were previously reported as 
causing MODY (16). Two HNF1A protein variants 
(p.S3C, p.G151S) were novel.
All three bioinformatics tools (SIFT, PPH2 and 
Provean) predicted both novel variants and p.
https://doi.org/10.11613/BM.2018.020703 Biochem Med (Zagreb) 2018;28(2):020703 
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496 c.8C>G S3C missense no D D D 37 1 24.17 insulin + glinide 0
042 c.451G>A G151S missense no D D D 35 2 26.37 metformin+ SU+DPP4I 0
294
c.685C>T R229X nonsense yes (14) protein truncating
25 2 19.05 glinide
0
466* 36 3 N/A insulin
245
c.751G>A A251T missense yes (15) N D N
39 2 27.14 diet
0343* 50 2 23.80 diet
345* 53 2 23.88 IFG, diet
083
c.862G>T G288W missense no† N D N
38 2 38.40 diet
0.0001
337* no DM 2 30.86 no DM
379 c.872dup G292 fsdupC frameshift yes (14) protein truncating 23 2 23.95 insulin 0
380 c.1136_ 1137delCT
P379 
fsdelCT frameshift yes (14) protein truncating 16
un- 
known 22.28 diet 0
055
c.1136C>G P379R missense yes (14) D D D
28 2 19.94 insulin
0
385* N/A 2 29.69 N/A
072 c.1544C>T T515M missense no† D D N 33 2 27.99 insulin 0.00002
*Affected relative. †Different amino acid reported in this position in subject with diabetes in the literature. ‡At median 10 years 
from diagnosis of diabetes. DM - diabetes mellitus. BMI - body mass index. IFG - impaired fasting glucose. SIFT - Sorting Intolerant 
From Tolerant. PPH2 - Polyphen 2. N – predicted as neutral. D - predicted as damaging. SU – sulphonylurea derivatives. DPP4I - 
dipeptidyl peptidase 4 inhibitor. N/A - not available.
Table 2. Molecular and clinical characteristics of subjects with rare HNF1A variants identified in this study
P379R to be functionally damaging. Variant p.
T515M was predicted as damaging by two bioin-
formatics tools (SIFT and PPH2), while Provean pre-
dicted it as neutral. Variants p.A251T and p.G288W 
were predicted as neutral by SIFT and Provean; on 
the other hand PPH2 predicted them as damag-
ing.
Two out of nine identified allelic variants were pre-
sent in the individuals from ExAC (c.862G>T, 
p.G288W and c.1544C>T, p.T515M) and none of the 
allelic variants were present in the non-diabetic in-
dividuals from T2D-GENES project. 
Family data was available for 3 families: those with 
protein variants p.A251T, p.P379R and p.G288W 
(Figure 3). The p.A251T variant co-segregated with 
a milder form of dysglycaemia not typical for 
MODY. The diabetic mother of the proband with 
p.P379R has the same variant, while the other non-
diabetic family members do not carry the variant. 
The mother of the proband with p.G288W carries 
the same variant, but does not have diabetes at 
age of 66 years, despite being obese. Unfortunate-
ly, it was not possible to perform co-segregation 
studies of the novel variants with diabetes due to 
the unavailability of other family members.
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Figure 3. Family trees of probands with variant A251T, G288W and P379R. Probands marked with an arrow; shaded – affected with 
diabetes; NM - tested and mutation found; NN - tested and no mutation found. IFG - impaired fasting glucose. N/A - not available. 
yr - years.
Based on the evidence discussed above, we 
showed that assigning disease-causality of the 
identified rare variant is complex and it may not 
be possible to provide a definitive answer. Taking 
all above into account, we concluded that six 
probands have disease-causing or likely disease-
causing protein variants (p.S3C, p.G151S, p.R229X, 
p.G292fs, p.P379fs and p.P379R). The protein vari-
ants p.G288W and p.T515M have weak evidence of 
causing a MODY phenotype. Protein variant p.
A251T remains of unknown significance, and may 
be associated with reduced penetrance of dysgly-
caemia.  
The prevalence of HNF1A-MODY in Croatia
In this study 13 probands and family members out 
of 477 individuals with C-peptide positive and beta 
cell antibody negative diabetes, diagnosed before 
45 years of age, had a rare HNF1A allelic variant. As 
discussed above, 8 subjects (6 probands and 2 
family members) carried allelic variants that had 
good evidence for causing MODY. The remaining 5 
individuals have variants which may be of lower 
disease penetrance or increase risk of type 2 dia-
betes, without causing a MODY phenotype. There-
fore, 2.7% (95% CI 1.25 - 4.15%) of our study partici-
pants carry rare HNF1A allele variants and 1.7% 
(95% CI 0.54 - 2.86%) have HNF1A-MODY.
The Croatian Institute of Public Health records 
from 2015 state that in total there were 260,092 in-
dividuals registered with diabetes in Croatia, 90% 
with T2D, and that 7.3% of subjects with T2D had 
diabetes onset before the age of 45 years. There-
fore, this would suggest approximately 281 (95% 
CI 257 - 304) HNF1A-MODY cases in Croatia and a 
prevalence of 66 (95% CI 61 - 72) cases per million 
of population. 
Clinical outcome of the study
Among 4 study participants identified to have HN-
F1A-MODY and treated with insulin, 2 were 
changed from insulin to an SU treatment and their 
diabetes remains well controlled. The remaining 2 
had significantly longer durations of diabetes (26 
and 30 years), therefore, it was considered by the 




DM diagnosed at 50 yr
41 yr, NM,
DM diagnosed at 38 yr
48 yr, NM,
DM diagnosed at 39 yr
40 yr, NM,
DM diagnosed at 28 yr
69yr , NM,






53 yr, NM, IFG 27 yr, NN 23 yr, NN
40 yr, NN 37 yr, NN
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appropriate, so they continued receiving insulin 
treatment.
Discussion 
This is the first study to identify individuals with 
monogenic diabetes in Croatia. We identified 13 
subjects with 9 different rare HNF1A allelic variants 
in 477 individuals with C-peptide positive and beta 
cell antibody negative diabetes, diagnosed before 
45 years of age. Eight of them have HNF1A-MODY. 
On this basis, we have calculated that 1.7% (95% CI 
0.54 - 2.86%) of subjects in our study group have 
HNF1A-MODY, which corresponds to a prevalence 
of 66 (95% CI 61 - 72) cases per million of popula-
tion. 
In the literature, estimations of the proportion of 
all MODY cases (including other causative genes) 
vary between 0.14% and 4.2% of all reported dia-
betes cases (9,18–23). In 1981, a German study re-
ported a prevalence of clinical MODY of 0.14% of 
total 40,927 diabetes cases, which corresponded 
to 70 cases per million of the population (19). With-
in the Norwegian HUNT2 study of 1972 subjects 
with diabetes, a minimum prevalence of HNF1A-
MODY of 0.4% was calculated, corresponding to 
63 cases per million (21). UK studies reported a 
minimum MODY prevalence of 108 per million us-
ing data from the diagnostic sequencing laborato-
ry (half of the cases had HNF1A-MODY) and 84 cas-
es per million from a population-based approach 
(only HNF1A-MODY) (9,22). These results from oth-
er European countries, calculated with various 
clinical or sequencing approaches, are compara-
ble to our estimations. 
The advantage of our study versus most of the so 
far published is the fact that all C-peptide positive 
and beta cell antibody negative participants diag-
nosed up to age of 45 years had HNF1A sequenc-
ing, so fewer cases were likely to be missed by nar-
rowing of selection criteria for genetic testing. The 
“classic” clinical criteria for MODY diagnosis in-
clude onset of diabetes before age of 25 years, in-
sulin-independence and at least two-generational 
family history of diabetes (24–26). Using this gen-
erally accepted cut off for diabetes onset we would 
miss more than three quarters of the HNF1A-MO-
DY subjects identified in our study. 
Despite having no difference in age of onset from 
the young adults without an HNF1A allelic variant, 
those with rare HNF1A allelic variants otherwise 
had typical features of MODY: they were leaner, 
with lower C-peptide in keeping with beta cell de-
fect and had less dyslipidaemia. 
A limitation of our study is the uncertainty that we 
selected a representative sample of all young 
adult diabetes onset individuals in Croatia. Al-
though individuals throughout Croatia were invit-
ed, they needed to travel to Zagreb to be recruit-
ed, so the participation of non-Zagreb residents 
was limited. A further limitation of this study is 
that we did not use a gene-dosage method such 
as multiplex ligation-dependent probe amplifica-
tion (MLPA) to detect larger deletions which are 
missed in Sanger sequencing. However, this is rela-
tively uncommon cause (estimated 3%) of HNF1A-
MODY (27). Another limitation is difficulty in abso-
lutely assigning disease causality to an identified 
allelic variant. This is a challenge in many genetic 
disorders. For instance, allelic variants that were 
previously perceived as disease-causing have now 
been identified in populations comprising mostly 
healthy individuals, which leads us to question 
their pathogenicity. Careful assessment of identi-
fied variants will inform this process. Formal func-
tional assessment of the variants we identified 
would provide further information about the likely 
effects, but may not completely define the wide 
range of phenotypes, which can be associated 
with the same variant (28). We also had difficulty in 
recruiting family members of the probands to es-
tablish co-segregation of the variant with diabetes 
for all the HNF1A variants found. This is likely to re-
flect the “real world” experience of clinicians, at-
tempting to assess variants found through genetic 
testing, and reinforces the importance of diagnos-
tic laboratories in collating data on variants of un-
certain significance. 
A final limitation is that we have investigated the 
prevalence of HNF1A-MODY only, as the most com-
mon form of monogenic diabetes, so the preva-
lence of other MODY subtypes, such as GCK-, HN-
F4A- or HNF1B-MODY in Croatia remains unknown.
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The exact prevalence of MODY can be determined 
only by population-based sequencing data, how-
ever, this is unlikely to be available in the near fu-
ture. 
In conclusion, in this study we calculated a mini-
mum prevalence of 66 (95% CI 61 - 72) HNF1A-MO-
DY cases per million of population in Croatia, 
which is consistent with the estimated prevalence 
of this form of monogenic diabetes in other Euro-
pean countries. Currently, the vast majority of HN-
F1A-MODY cases in Croatia remain unidentified, 
therefore the affected individuals are not receiv-
ing optimal management. Further advantage of 
establishing a molecular diagnosis is cascade 
screening of relatives, with potential change in the 
treatment of those with diabetes and giving a 
prognostic advice to currently non-diabetic carri-
ers. In this study two individuals were able to dis-
continue insulin for oral hypoglycaemia treatment, 
demonstrating the potential benefits of making a 
molecular diagnosis. We believe that our study 
strongly supports the introduction of genetic test-
ing for MODY in Croatia. Further work including 
health economic evaluation would be required to 
establish an appropriate pathway.
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